EHA 2022 | The future of immunotherapy for the treatment of ALL
Ryan Cassaday
• 20 Jun 2022
Ryan Cassaday, MD, University of Washington, Seattle, WA, shares some insights into the important role of immunotherapy in the treatment of acute lymphoblastic leukemia (ALL), and comments on where the field is moving. Dr Cassaday first highlights the importance of optimizing agent selection, sequencing, and timing, and then discusses the future role of CAR-T therapy in this space. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding from Amgen, Kite/Gilead, Merck, Pfizer, Servier, and Vanda Pharmaceuticals; consulting/honoraria from Amgen, Kite/Gilead, and Pfizer; and spouse is employed by and owns stock in Seagen.
